Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_assertion type Assertion NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_head.
- NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_assertion description "[We demonstrate the clinical usefulness of a panel of beta2 integrins (CD11a, CD11b and CD11c) in accurate prediction of AML-M3, and recommend inclusion of this immunophenotypic analysis to identify patients who require ATRA therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_provenance.
- NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_assertion evidence source_evidence_curated NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_provenance.
- NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_assertion SIO_000772 16764927 NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_provenance.
- NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_assertion wasDerivedFrom ctd_human-20150221 NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_provenance.
- NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_assertion wasGeneratedBy ECO_0000218 NP19793.RAseSWDEaS_a4fxiUO8-7vhPwmrcGeCMvm7SRnBcCKFv0130_provenance.